Actualités du congrès de l’ESMO (European Society For Medical Oncology) 2019 en oncologie digestive (notice n° 664333)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03815cam a2200289 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193624.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Neuzillet, Cindy |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Actualités du congrès de l’ESMO (European Society For Medical Oncology) 2019 en oncologie digestive |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2019.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 7 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Cet article propose un résumé des présentations marquantes en oncologie digestive du congrès de l’ESMO (European Society For Medical Oncology) qui s’est déroulé à Barcelone fin septembre 2019. Parmi elles, une analyse ancillaire de l’étude de phase III IDEA France a confirmé que l’ADN tumoral circulant est un facteur pronostique majeur dans les cancers coliques opérés. Chez les patients atteints de cancer colorectal métastatique avec mutation de BRAF V600E, l’étude de phase III BEACON a démontré la supériorité du triplet d’inhibition encorafénib (anti-RAF)/binimétinib (anti-MEK)/cétuximab (anti-EGFR) par rapport à la chimiothérapie par FOLFIRI et cétuximab, faisant de ce triplet un nouveau standard en deuxième ligne. Dans les cancers digestifs non colorectaux, l’immunothérapie par nivolumab (anti-PD1) a fait la preuve de son efficacité vs. une chimiothérapie de deuxième ligne dans les carcinomes épidermoïdes de l’œsophage avancés dans l’étude de phase III ATTRACTION-03. L’étude ClarIDHy a montré que l’ivosidénib, inhibiteur de la forme mutée d’ IDH1, améliore la survie sans progression par rapport au placebo en phase III chez les patients atteints de cholangiocarcinome avec mutation d’ IDH1. Le riprétinib est le nouveau traitement de référence en quatrième ligne des tumeurs stromales gastro-intestinales avancées sur la base des résultats de l’étude de phase III INVICTUS qui a montré sa supériorité par rapport au placebo. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This article presents a summary of the key presentations in digestive oncology of the European Society For Medical Oncology (ESMO) conference held in Barcelona at the end of September 2019. Among them, an ancillary analysis of the IDEA France Phase III study confirmed that circulating tumor DNA is a major prognostic factor in localized colon cancers. In patients with metastatic colorectal cancer with BRAF V600E mutation, the BEACON phase III study demonstrated the superiority of the inhibition triplet encorafenib (anti-RAF)/binimetinib (anti-MEK)/cetuximab (anti-EGFR) compared to chemotherapy with FOLFIRI and cetuximab, making this triplet a new standard in the second line setting. In non-colorectal gastrointestinal cancers, nivolumab (anti-PD1) immunotherapy has been shown to be effective vs. second-line chemotherapy in advanced squamous cell carcinoma of the esophagus in the ATTRACTION-03 Phase III study. The ClarIDHy Phase III study has shown that ivosidenib, an inhibitor of the mutated form of IDH1, improves progression-free survival over placebo in patients with cholangiocarcinoma with IDH1 mutation. Ripretinib is the new fourth-line reference treatment for advanced gastrointestinal stromal tumors based on the results of the INVICTUS Phase III study, which showed superiority over placebo. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer oesogastrique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer colorectal |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | carcinome hépatocellulaire |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer du pancréas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer des voies biliaires |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | oesogastric cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hepatocellular carcinoma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pancreatic cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biliary tract carcinoma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | colorectal cancer |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 26 | N° Supp 6 | 2019-09-20 | p. 14-24 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2019-HS6-page-14?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2019-HS6-page-14?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux